首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Effects and Possible Mechanisms of Puerarin to Treat Endometriosis Model Rats
【24h】

The Effects and Possible Mechanisms of Puerarin to Treat Endometriosis Model Rats

机译:葛根素治疗子宫内膜异位症模型大鼠的影响和可能机制

获取原文
           

摘要

Objective. To explore the effects of puerarin to treat endometriosis (EMT) model rats and the possible regulatory mechanisms.Methods.EMT model rats were surgically induced by autotransplantion of endometrial tissues. The appropriate dosage of puerarin to treat EMT model rats was determined by observing the pathologic morphology of ectopic endometrial tissues and by detecting the levels of estradiol (E2) and prostaglandin E2 (PGE2) of both serum and ectopic endometrial tissues. The related genes and proteins of ectopic endometrial tissues were analyzed by Real-time PCR and immunohistochemistry (IHC) to explore the possible mechanisms.Results. Puerarin could reduce the levels of E2 and PGE2 and prevent the growth of ectopic endometrium tissues by inhibiting the expression of aromatase cytochrome P450 (p450arom) and cyclooxygenase-2 (cox-2); puerarin could adjust the anabolism of E2 by upregulating the expression of 17β-hydroxysteroid-2 (17β-hsd-2) and downregulating the expression of 17β-hydroxysteroid-1 (17β-hsd-1) of the ectopic endometrium tissues; puerarin could increase the expression of ERβand improve the inflammatory microenvironment of EMT model rats.Conclusions.Our data suggest that puerarin has a therapeutic effect on EMT model rats and could be a potential therapeutic agent for the treatment of EMT in clinic.
机译:客观的。为了探讨葛根素治疗子宫内膜异位症(EMT)模型大鼠的影响及可能的调节机制。通过子宫内膜组织的自同淀粉类药物诱导方法。通过观察异位子宫内膜组织的病理形态并通过检测血清和异位子宫内膜组织的雌二醇(E2)和前列腺素E2(PGE2)的水平来确定葛根素治疗EMT模型大鼠的适当剂量。通过实时PCR和免疫组织化学(IHC)分析相关基因和异位子宫内膜组织的蛋白质以探讨可能的机制。结果。葛根素可以降低E2和PGE2的水平,并通过抑制芳族酶细胞色素P450(P450AROM)和环氧化酶-2(COX-2)的表达来防止异位子宫内膜组织的生长;葛根素可以通过上调17β-羟基甾醇-2(17β-HSD-2)的表达和下调异位子宫内膜组织的17β-羟基 - 甾醇-1(17β-HSD-1)的表达来调节E2的合成代谢物;葛根素可以增加ERβ和改善EMT模型大鼠炎症微环境的表达。结论。我们的数据表明,葛根素对EMT模型大鼠具有治疗效果,并且可以是临床治疗EMT的潜在治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号